Amendment to CTA

Examples	Must be approved by the DKMA (enclose Annex 2) http://eudract.emea.europa.eu/docs/forms/Substantial_Amendments.doc	Notification only (*incl. XML file)	Do not submit to the DKMA
Changes to the study protocol			
Trial design	X		
Purpose of trial	X		
Changes relating to the **safety** of the trial subjects	X		
Total number of trial subjects	X		
Change in **number of Danish trial subjects,** but not in the total number of trial subjects		X*	
Number of trial subjects per trial site			X
Inclusion/exclusion criteria	X		
Safety monitoring	X		
Changes to **participant information sheets & informed consent forms**			X
Recruitment procedure			X
Measures of efficacy	X		
Addition or deletion of tests or measures	X		
Duration of exposure to the investigational medicinal product (IMP)	X		
Extension of the study **beyond the period** specified in the application form due to a prolonged recruitment period		X	
Change of dosage of the IMP(s)	X		
Change of comparator	X		
Change of statistical analysis	X		
Correction of **typographical errors** in the trial protocol or other study documentation			X
Changes related to the trial arrangements			
Changes to the **principal investigator's research team**, e.g. sub-investigator			X
Changes in **funding arrangements**			X
Changes to **recruitment material for trial**			X

subjects			
Change in **insurance or indemnity arrangements** related to the study			X
Change of **principal investigator** at a trial site		X*	
Change/addition of **sub-investigator**			X
Appointment of a **new coordinating investigator**	X		
Addition of a new trial site in a study in Denmark	X		
Removal of trial sites		X*	
Change of **sponsor**(s) or **sponsor's legal representative**	X		
Change of **the CRO** (e.g., applicant, monitoring, SUSAR reporting)	X		
Changes related to the IMP(s)			
Changes of **quality or safety of any IMP** used in the trial	X		
Change of **name** or **code** of IMP(s)		X*	
Change of immediate **packaging material**		X	
New manufacturer(s) of active substance	X		
Manufacturing process of the active substance, e.g. synthetic route, extension of acceptance criteria, change in physicochemical properties	X		
Manufacturing process of the active substance, e.g. scale-up, modification of process parameters	X		
Specification of active substance, e.g. extension of acceptance criteria, deletion of tests	X		
Manufacture of the medicinal product (scale-up notification not required)	X		
Specification of the investigational medicinal product, e.g. extension of acceptance criteria, deletion of tests	X		
Specification of excipients where these may affect product performance, e.g. change in particle size distribution	X		
Shelf-life incl. after first opening and reconstitution, e.g. reduction of shelf-life, restriction of storage conditions. (refer to the CHMP guideline**)	X		
Significant changes to the **formulation**, e.g. change in composition	X		
Storage conditions	X		
Test procedures of the active substance	X		

Test procedures of the investigational medicinal product	X		
Test procedures of non-pharmacopoeial excipients	X		
Change of **manufacturing / packaging/ labelling site** of the investigational medical product	X		
Change of the investigational medicinal product's **release or importing site in the EU**	X		
Changes to non-clinical pharmacology and toxicology data and clinical data			
New pharmacological results, or new interpretations of existing pharmacological tests. Results of new toxicity tests, new interpretations of existing toxicity tests, and results of new interaction studies.	If relevant to the ongoing trials (i.e. altered risk/benefit assessment)		
Safety related to a clinical trial or human experience with the investigational medicinal product, results of new clinical pharmacology tests, or new interpretations of existing clinical pharmacology tests, results of new clinical trials, or new interpretations of existing clinical trial data, new data from human experience with the investigational medicinal product, new interpretation of existing data from human experience with the investigational medicinal product.	If relevant to the ongoing trials (i.e. altered risk/benefit assessment)		
Investigator's Brochure, if the risk/benefit ratio is altered	X		
Investigator's Brochure, annual update without altered risk/benefit ratio		X	

** (CHMP/QWP/185401/2004)

http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-10/18540104en.pdf

A fee must be paid for all amendments that are to be approved by the Danish Medicines Agency. Please see the following link: http://www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=10155.